Funding for this research was provided by:
Bristol-Myers Squibb Foundation
Received: 23 March 2020
Accepted: 5 August 2020
First Online: 14 August 2020
Ethics approval and consent to participate
: The study was approved by the medical ethical committee of the Amsterdam University Medical Center, location VU Medical Center, MEC-number 2019.710. Participants will be included only after written informed consent.
: Not applicable.
: CD, FS, JV, SH, JD, MF, DH, PV, IHB, LM, JGV and DOLdeclare no competing interests. TG receives consultation fees from TILT Biotherapeutics, DCPrime, Macrophage Pharma and Partner Therapeutics, and receives research support from Marcrophage Pharma and Idera Pharmaceuticals, outside the submitted work. TR reports research support from Abbvie Pharmaceuticals ad participates in advisory boards of Roche, MSD, and Abbvie. Suresh Senan reports consulting/advisory fees from AstraZeneca, Merck, Celgene and Eli Lilly. His department has received research funding from AstraZeneca, ViewRay Inc. and Varian, outside the submitted work. IB reports consulting/advisory fees from AstraZeneca, MSD, Boehringer Ingelheim, Pfizer, Takeda, Celgene, Roche, BMS and Eli Lilly. His department has received research funding from AstraZeneca, BMS, Boehringer Ingelheim, HeatBiologics, Roche and MSD outside the submitted work.